Morgan Stanley Immunovant, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Immunovant, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,309,061 shares of IMVT stock, worth $63.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,309,061

Previous 1,310,050 76.26%

Holding current value

$63.5 Million

Previous $36 Million 76.26%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	N/A	999,011 Added 76.26%	2,309,061 $63.5 Million
Q1 2025 May 15, 2025	BUY	N/A	299,426 Added 29.63%	1,310,050 $36 Million
Q4 2024 Feb 14, 2025	BUY	N/A	192,882 Added 23.59%	1,010,624 $27.8 Million
Q3 2024 May 14, 2025	BUY	$27.51 - $27.51 $19,367 - $19,367	704 Added 0.09%	817,742 $22.5 Million
Q3 2024 Nov 14, 2024	BUY	$27.51 - $27.51 $19,367 - $19,367	704 Added 0.09%	817,742 $22.5 Million
Q2 2024 May 14, 2025	SELL	$25.1 - $31.61 $4.86 Million - $6.12 Million	-193,586 Reduced 19.16%	817,038 $21.6 Million
Q2 2024 Oct 17, 2024	SELL	$25.1 - $31.61 $3.04 Million - $3.82 Million	-120,923 Reduced 12.89%	817,038 $21.6 Million
Q2 2024 Aug 14, 2024	SELL	$25.1 - $31.61 $3.04 Million - $3.82 Million	-120,923 Reduced 12.89%	817,038 $21.6 Million
Q1 2024 Oct 17, 2024	BUY	$30.27 - $43.79 $3.66 Million - $5.3 Million	120,923 Added 14.8%	937,961 $30.3 Million
Q1 2024 Aug 16, 2024	BUY	$30.27 - $43.79 $12.3 Million - $17.8 Million	406,458 Added 76.47%	937,961 $30.3 Million
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $12.3 Million - $17.8 Million	406,458 Added 76.47%	937,961 $30.3 Million
Q4 2023 Aug 16, 2024	SELL	$31.31 - $44.19 $8.94 Million - $12.6 Million	-285,535 Reduced 34.95%	531,503 $22.4 Million
Q4 2023 Feb 13, 2024	BUY	$31.31 - $44.19 $6.03 Million - $8.51 Million	192,620 Added 56.84%	531,503 $22.4 Million
Q3 2023 Nov 15, 2023	SELL	$18.55 - $39.96 $3.68 Million - $7.92 Million	-198,173 Reduced 36.9%	338,883 $13 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $4.4 Million - $7.36 Million	309,965 Added 136.49%	537,056 $10.2 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $867,962 - $1.12 Million	56,841 Added 33.39%	227,091 $3.52 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $512,827 - $1.38 Million	77,819 Added 84.19%	170,250 $3.02 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $264,253 - $428,318	-67,240 Reduced 42.11%	92,431 $516,000
Q2 2022 Oct 27, 2022	SELL	$3.38 - $5.65 $231,026 - $386,183	-68,351 Reduced 29.98%	159,671 $622,000
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $231,026 - $386,183	-68,351 Reduced 29.98%	159,671 $622,000
Q1 2022 Oct 27, 2022	BUY	$5.06 - $8.77 $345,856 - $599,438	68,351 Added 42.81%	228,022 $1.26 Million
Q1 2022 May 13, 2022	SELL	$5.06 - $8.77 $1.36 Million - $2.36 Million	-268,888 Reduced 54.11%	228,022 $1.26 Million
Q4 2021 Feb 14, 2022	SELL	$7.33 - $9.32 $2.7 Million - $3.43 Million	-368,336 Reduced 42.57%	496,910 $4.23 Million
Q3 2021 Nov 15, 2021	BUY	$7.01 - $11.37 $6.07 Million - $9.84 Million	865,246 New	865,246 $7.52 Million

Others Institutions Holding IMVT

# of Institutions

192

Shares Held

78.7M

Call Options Held

401K

Put Options Held

354K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account